<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 62 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page61.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=62">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 62 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 62</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=62"><img src="../thumb/62.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.5.3 / 1.5.4                                          2020-04 / 31
       induc. eg. carbamazepine/phenytoin/barbits./rifampicin, incr. plasma   Ac.mania in bipol.disord: Recomm.dos: 10 mg once dly. Dos.  (S5) IM INJ, 35/2.6.5/0307
       conc.with potent inhibits.of CYP3A4 eg.macrolides & azole antifung.  adjustm.within range of 5-20 mg/ day to occur at interv.of not less   Indications: Agitat.&disturb.behav.in schizophren. & relat.psychos.,
       ZOXADON, Pharma Dynamics [P/S]  than 24 hrs.if indicat.    ac.mania assoc. with bipol.I disord.when oral ther.not appropriate.
                                                                  702949-001: 10 mg, sngl.vials, R190,05
                                     Prev.recurr.in bipol.disord: Recomm.init.dos: 10 mg/ day. For
       Risperidone                   those receiv. Zylena for manic episod. cont.ther.at same dos. Incr.  Dosage: Tfd.to oral ther.as soon as clinic.indicat. IM use only.
       Indications: Ac.& chron.schizophren.psychos. & relat. psychos.  dos.over 10 mg advis. only aft.clinic.assessm.& should occur at in-  10 mg as sngl.IM inj. May be rep.2 hrs.aft.1  dos.& again 4 hrs.aft.2   nd
                                                                                    st
       where posit.&/ or negat.sympts.are promin., behav.disturbs.in pts.  terv. of not less than 24 hrs. Safety of dos.above 20 mg/day not est.  dos.if necess. Dly.dos.exceed. 30 mg not eval.
       with dement. when aggressiven. /activ.disturbs./psychot.sympts.are   Contraindications: Known narrow-angl.glauc. risk, safety in childr.  Contraindications: Safety in pregn.& lactat.& childr. und.18 yrs.
       promin., conduct & disrupt.behav. disords.in childr. 5-12 yrs.with sub-  und.18 yrs.not est.  not est., known narrow-angl. glauc. risk, concom.fluoxetine/parenter.
       aveg.intellect. funct./ment.retard. where destruct. behav.is promin.  Side effects: Freq: Orthostat.hypotens., hypertens., pneumon.,   benzodiazep. not recomm.
       (S5) TABS, A41/2.6.5/0468, 0445, 0446, 0469, 0470  constip., dry mouth, incr. appet., urin.incontin., glycosur., vaginit.,   Side effects: Asthen., bradycard.(ser./sev.with IM use with apnoea
       711511-001: 0,5 mg, 30, R115,61  incr. prolactin, chest pain, fev., flu-like sympts., asthen., incr. cho-  & ventric.tachydysrhythm.), neurolept.malign.syndr., orthostat.hypo-
       711512-001: 1 mg, 30, R223,42  lester./triglycerid./ALT/SGPT/ AST/ SGOT/ gluc., eosinophilia., pe-  tens., tachycard., hypotens., GI disturbs., weight gain, hyperglycaem.
       711513-001: 2 mg, 30, R477,00  riph.oed., weight gain., agitat., personality disord., mental/mood   incl.diabet.coma & ketoacidos., exacerbat. pre-exist.diab., hypertri-
       721750-001: 3 mg, 30, R592,59  changes, anx., euphor., hostil., hallucinats., akathis., dizzin., amnes.,   glyceridaem., periph.& low. extremity oed., CNS effs.incl.seiz., incr.
       721752-001: 4 mg, 30, R592,59  nervousn., Parkinsonism, dyskines., movem.disord., myoclon.,   tard.dyskines.risk with long-term treatm., rash, photosens.react.,
       Dosage: Schizophren: When switch.from other antipsychot.& if   twitch., somnol., speech disord. Less freq: Abnorm.vis., photos-  priapism, bld.dyscras., hepatit., allerg.reacts., ven.thromboembol.,
       medic.appropr.discont.prev. treatm. grad.while init.Zoxadon. Init. Zox-  ens., bradycard., tachycard., pharyngit,. cough., dyspeps., abdom.  rhabdomyolys., eosinophil., incr.incid.of abnorm. gait/falls/urin. in-
       adon in place of next sched.inj.when switch.from depot antipsychot.   pain, N&V, incr.salivat., rash., acne, dry skin., joint/ extremity pain,   contin./pneumon./ death/CVA’s incl.stroke in elderly with dement.
       Re-eval.need for cont.exist.anti-Parkinson meds.per.  dysmenorrh., sweat., thirst, leucopaen., weight loss., apathy., seiz.,   relat.psychos., hallucinat.& Parkinsonian symptomatology in drug
       Adults: Admin.1-2xdly. Init. 2 mg/day. May be incr.to 4 mg on 2nd   drowsin., headache, confus., insomn., paraesthes., stutter., abnorm.  induc. psychos. assoc.with Parkinsons
       day, indiv.furth.if reqd. Most pts.benef.from dly.dos.betw. 4-8 mg/day.   gait, trem., hyperton. Freq.unknown: Diplop., ventric. extrasystol.,   Special precautions: Contin.respond.pts.on low. dos.to maint.
       Dos. above 6 mg/day admin.2x dly.were assoc.with more extrapyra-  palpitat, ven. thromboembol., dyspn., hepatit., incr.alkaline phos-  remiss., elev.prolact.lev.persist. modestly dur.chron.admin., incr.
       mid.sympt./other adverse effs. A slow.titr.phase & low.start./maint.  phat/tot.bilirub., skin rash, prurit, urticar., rhabdomyolys., decr.li-  mammary gland neoplasms consid.prolact.mediat.report.in rodents
       dos.may be appropr.in some pts.esp.with first ac.psychot. episod.   bido, priapism, menstr.changes, discont.react., thrombocytopen.,   on chron.antipsychot.medicat., concom.centr.act. agents & alcoh.,
       Dos.above 10 mg/day have not been shown to be superior in effic.&   anaphylact.react., angio-/fac. oed., allerg.react., diabet.coma/  discont.if S&S of neurolept. malign. syndr./high fev.observ., hist.of
       may incr.incid.of S/E. Max.tot.dly.dos: 16 mg/day. Add benzodiazep.   ketoacidos., hypercholesterolaem., hyperglycaem., hypertriglyc-  seiz./ condits. assoc.with seiz./low.seiz.thresh., hepat. impairm./
       if addit.sedat.reqd.          eridaem., pancreatit., water intoxic.  concom.potent.hepatotox.meds., monit. exist.diab.for worsen.gluc.
       Elderly: Init. 0,5 mg 2x dly.adjust.in 0,5 mg 2xdly. increm.to 1-2 mg 2x dly.  Warnings and special precautions: Effectiven. for long.than 6   contr., monit.pts.start. treatm.at risk of diab.for hyperglycaem., fast.
       Behav.disturbs.in pts.with dement: Init. 0,25 mg 2xdly. Indiv.if   wks.not est.in control.stud., period. re-assesm.to determ.need for   bld. gluc.if hyperglycaem.develops,some pts.req. continuat.of anti-
       necess.in increm. of 0,25 mg 2xdly.not more freq.than every other   maint.treatm., safety in pregn.& lactat. not est., discont.grad., dis-  diabet.treatm.despite discont.of suspect.drug, concom.meds.known
       day. Optim. dos: 0,5 mg 2xdly.with some benefit.from dos.of upto   cont.if any clinic.NMS manifestat./high fev.observ., hist. of seiz./  to incr.QTc interv./ congenit.long QT syndr./CHF/heart hypertrophy/
       1 mg 2xdly. Once target.dos.reach.consid. once dly.dos. Eval.cont.  condits.assoc.with seiz./low.seiz.thresh., consid. discont./dos.  hypokalaem.& hypomagnesaem., concom. BP low.meds.other than
       treatm.reg.                   reduct.if tard.dyskines. S&S develop, tard.dyskines.risk incr.with   alpha-1 adrenerg. antagon., subst.induc./inhibit.CYP1A2 isoenzyme
       Conduct & disrupt.behav.disords.in childr.5-12 yrs: &lt;50 kg:   long-term expos., S&S of hepat.impairm., pre-exist.condits. assoc.   may affect olanzapine pharmacokinet., poss.reduc. dos. with concom.
       Init.0,01 mg/kg once dly. Indiv. adjust. in increm.of 0,01 mg/kg once   with limit.hepat.funct.reserve, concom. potent. hepatotox.meds.,   CYP1A2 inhibit., plasma clear.in smokers higher, card.pts.due to or-
       dly.not more freq.than every other day if need. Recomm.maint. dos:   period.assessm.of transaminas. recomm.in hepat.dis. predispos.  thostat. hypotens. risk (esp.IM admin.), sympt.prostat. enlargem., narr.
       0,02-0,04 mg/kg once dly. Mean dos: 0,03 mg/kg once dly. Eval.  risk fact. in elderly with dement.relat.psychos.to incr. mortality incl.   angle glauc., paralyt.ileus & relat. condits., recent MI hist./unstable
       ongoing need reg.             &gt;80 yrs./sedat./concom. benzodiazepines & pulm.condits., elderly   card.dis., S&S of hepat. impairm., pre-exist.condits.assoc.with limit.
       Contraindications: Safety & effic.in childr.und.5 yrs. for conduct   with dement. tak.stroke risk into account., monit.exist. diab. for   hepat. funct. reserve, low leucocyte/neutrophil counts, meds.induc.
       & other disrupt.behav.disords.not est., safety in pregn.& lactat.not   worsen.gluc.contr., monit.pts.start. treatm. at risk of diab.for hyper-  bone marrow depress./toxic., bone marrow depress., hypereosno-
       est., Lewy antibody dement., safety & effic.in childr.und.15 yrs. for   glycaem.sympt., fast. bld.gluc.if hyperglycaem.develops, some re-  phil.condits., myeloproliferat. dis., condits.contrib.core body temp.
       schizophren.not est.          quir. contin.anti-diabet.treatm.despite Zylena discont., elev.prolact.  elevat., pts.at risk of aspirat.pneum., monit. high risk suic.pts., reg. BP
       Side effects: Freq: Weight gain, headache, fatig., rhinit., insomn.,   lev.persist.modestly dur. chron. admin.with incr.in mammary gland   monit.of pts.&gt;65 yrs., grad. discont., velotabs.contain phenylalanine
       agitat., anx., somnol., imp. concentrat., extrapyramid.disord., dizzin.,   neoplasms in rodents thought to be prolactin mediat., not recomm.  Drug interactions: May antagon.effs.of levodopa & dopamine ago-
       blurr. vis., constip., dyspeps., naus., skin rash, urin. incontin., erect./  in Parkinson’s dis., symptomat. prostat.enlargem., narr.angle glauc.,   nists, may enhanc.effs.of cert. antihypertens., reduc.eff.with activat.
       ejaculat./orgasmic dysfunct. Less freq: Decr.neutrophil &/ throm-  paralyt. ileus & relat.condits., rec.MI hist., unstab. heart dis., card.  charc., fluoxetine decr.clear., metabol.poss.induc.by carbamazepine
       bocyte count, incr. plasma prolact.lev. & assoc.manifestats., tard.   pts./condits.predispos.to hypotens. due to orthostat.hypotens.risk,   low.plasma lev., clear.decr.by CYP1A2 inhibit.
       dyskines. neurolept.malign.syndr., cerebrovasc. incid., orthostat.  monit.reg.for undesirab. alterat. in lipids, reg.BP monit.of pts. &gt;65
       hypotens., reflex tachycard., hypertens., vomit., abdom.pain, pria-  yrs., elev.AST&/ALT lev., S&S of hepat. impairm., pre-exist.condits.
       pism, gynaecomast., galactorrh., menstr.cycle disturbs., amenorrh.   assoc with limit.hepat. funct. reserve, concom.potent.hepatotox.  1.5.4  Others
       Unknown freq: Allerg.reacts., angioed., water intoxicat. due to   meds., period. assessm. of transaminas.recomm.in hepat. dis., dis-
       polydips./SIADH, body temp. disregulat., sedat.dos.depend. ex-  cont.treatm.if hepatit.diagn., leucopen./ neutropen., meds.induc.  FLUANXOL (MDR Listing)
       trapyramid. sympts.           bone marrow depress./ toxic., bone marrow depress., hypereosno-
       Warnings and special precautions: Epilep., concom.alcoh.& oth-  phil. condits., myeloproliferat.dis., condits.contrib.to elev. core body   ASPEN TRAZODONE, Aspen Pharmacare (Pty) Ltd
       er central.act.meds., excret.in breast milk, preventat.hypo-oestrog.  temp., aspirat.pneum.risk pts, supervis. pts. at risk of suicid., lact./  See Section 1.4.10
       bone loss ther. in premenopaus. women with second.amenorrh.of   galact.intol., improvem.in pt.condit.may take sev.days to wks., con-  BIO-SULPIRIDE 200, Biotech [P/S]
       &gt;6mnths., somet.diffic.to differen.advers.effs.from sympts. of un-  com. meds.incr.QTc interv.esp.elderly/ congenit. long QT syndr./CHF/  Sulpiride
       derly.psychos., Parkinsonian S/E poss. predict.of TD develop., TD   card.hypertrophy/ hypokalaem./ hypomagnesaem., concom.BP low-  Indications: Psychot./other psychiatric illn., ac./chron. schizophren.
       risk incr.with treatm. durat.& tot cumulat.dos., may mask TD S&S.,   er. meds. other than alpha-1 adrenerg.antagon., consid. low. start.  charact.by lack of social contact, depress.
       prescrib.in manner to minim.TD risk, reg. assess contin.ther., con-  dos.with fluvoxamine/other CYP1A2 inhib., activ.charcoal admin.2   (S5) TABS, 30/2.6.5/0511
       sid.discont.ther.if S&S of tard. dyskines., discont.all anti-psychot.&   hrs.bef./ aft.Zylena., concom.fluoxetine not recomm.  705386-001: 200 mg, 50, R400.95
       not essent. meds.if neurolept.malign.syndr. (NMS) devel., consid.  Interactions: Reduc.bioavail.with activat.charc., CNS eff.enhanc.  Dosage: Schizophren: Init.dos: 200-400 mg 2xdly.incr.if necess.to
       re-introduct.caref.& monit.aft.NMS recov. as NMS recurr.report.,   of other CNS depress.& alcoh., may antagon.effs.of levodopa &   max.1,2 g 2xdly. Usual maint: 400-800 mg dly.
       known CV dis.where grad. dos.titrat.recomm., consid.dos.reduct.if   dopamine agon., may enhanc.effs.of cert.antihypertens., QTc pro-  Contraindications: Phaeochromocyt., safety in pregn.& lactat.
       hypotens. develops., elderly, ren./liv.insuffic., excess. eat.in view of   longat. risk with meds.known to cause QTc prolongat., CYP1A2   not est., bone marr.depress., concom. meds.induc.leucopen.&
       poss.weight gain, dehydrat. risk in elderly dement.pts.with concom.  inhibit.incl.fluvoxamine decr. clear.,CYP1A2 induc.incr.clear., fluox-  bld.dyscras.
       furosemide, monit. gluc.contr.of exist.diab./hyperglycaem. sympt. in   etine incr. conc. & decr.clear., smok./carbamazepine/ omeprazole &   Side effects: Sleep disturbs., overstimulat., agitat., dry mouth, con-
       those at risk, pts.develop.hyperglycaem. sympt.dur.ther.to undergo   rifampicin.low.plasma lev.  stipat., urin.retent., mydrias., depress., convuls., nas.congest., tachy-
       fast.bld.gluc.test,cont. anti-diab. meds.poss.necess.despite ther.  card., ECG chang., postur.hypotens., miosis., blurr.vis., ejaculat.inhib.,
       discont., Parkinson’s dis./dement.with Lewy bodies.at risk for NMS   ZYPREXA, Eli Lilly [P/S]  impot., priapism, allerg.reacts., jaund., pigm.deposit.in skin & eyes
       & incr.psychot.meds.sens., pts.hist.on prev./ curr. risperidone use   Olanzapine.  with prolong.ther., corn.& lens opacit., photosens., bld.dyscras., ex-
       prior to cataract surg., poss. cerebrovascul.adverse event risk incl.   Indications: Psychot.disords., ac.mod.to sev. mania, prev.recurr.of   trapyramid. dysfunct., amenorrh., galactorrh., gynaecomast., mass
       cerebrovasc. accid.& TIA in elderly pts.with dement., re-eval.dos.on   manic/depress.episod.of bipol.disord.  gain, hyperglycaem., alt.gluc.tol., hypo-/hypertherm.
       discont.of carbamazepine & other hepat.enzyme induc., re-eval.dos.  (S5) TABS, 32/2.6.5/0685, 31/2.6.5/0058, 0060.  Special precautions: Manic/hypoman.pts. where sympts.poss.
       on fluoxetine/ paroxetine init./discontinuat., heredit probl.of galact.  864188-005: 2,5 mg, 28, R441,09  exacerb., elderly, debilit., imp. liv./kidn./CV/cerebrovasc.& resp.
       intol./Lapp lactase defic./or gluc.-galact. malabsorpt.  827509-006: 5 mg, 28, R650,39  funct., where sudd.BP drop undesir., Parkinson., effs.on vomit.cntr.
       Interactions: May antagon.eff.of levodopa & other dopamine ago-  827517-009: 10 mg, 28, R833,83  may mask sympts.of OD from other agents or GI obstruct., diab.,
       nists, carbamazepine & other hepat.enzyme induc.may decr.plasma   (S5) VELOTABS, 38/2.6.5/0030, 0073  epilept.receiv. anticonvuls.,
       lev., incr. plasma lev.with phenothiaz./TCA’s/some ß-block. & fluox-  707938-001: 5 mg, 28, R650,28  Drug interactions: Enhanc.activ.of CNS depress., antihypertens.
       etine/paroxetine, incr.valproate T max, incr. AUC & decr.clear.with   707939-001: 10 mg, 28, R833,83  act.of guanethidine & other adrenerg.neur.block.meds.reduc., act of
       venlafaxine, incr.bioavail. with cimetidine/ranitidine., T max of Li incr.  Dosage: Admin.as once-a-day dos. Safety of dos.above 20 mg/day   levodopa inhibit., potents adverse effs.of other antimuscarin.agents.
                                     not eval. Velotabs are bioequiv.to coat.tabs. Place Velotabs in mouth
       ZYLENA, (Unicorn) Akacia [P/S]  immed.aft.open.blister where it will rapid dissolv. in saliva or dispers.  CLOPIXOL, Lundbeck [P/S]
       Olanzapine.                   in full glass of water/bever. immed.bef.admin.  Zuclopenthixol decanoate.
       Indications: Psychot.disords., ac.epis.of mod.to sev. mania & pre-  Psychot.disords: Init. 5-10 mg/day with target dos.of 10 mg/day   Indications: Maint.treatm.of schizophren. incl.agitat., psychomot.
       vent.recurr.manic/depress.epis.in bipol. disord.  within several days. If indic.dos.adjustm.should occur at interv.of not   disturbs., hostility, suspiciousn., aggress., affect.react.
       (S5) TABS, 45/2.6.5/0447, 0448  less than 1 wk. Dos.range: 5-20 mg/day. Incr.above routine 10 mg/  (S5) DEPOT INJ, [P/S] R/2.6.5/52. 200 mg/ml.
       721652-001: 5 mg, 30, R474,38  day advis.only aft.clinic.assessm.  714852-007: 1x1 ml, R104,75
       721653-001: 10 mg, 30, R607,99  Ac.man.in bipol.disord: Init.dos:10 mg once dly. Dos.adjustm.  714852-023: 5x1 ml, R523,66
       Dosage: Admin.as once-a-day dos. Grad.discont  within range of 5-20 mg/day to occur at interv.of not less than 24   Dosage: Admin.deep IMI
       Psychot.disords: Init. 5-10 mg/day with target dos. of 10 mg/  hrs.if indicat.  200-400 mg at 2-4 wk.intervals. Init:100 mg, 1 wk. later (or when
       day within several days. Dos incr. should not be consid.bef.1 wk.of   Prev.recurr.in bipol.disord: Recomm.init.dos: 10 mg/ day. For   sympts.recur but not more than 4 wks. later) 100-200 mg. Maint:
       ther. Dos.rang. from 5-20 mg as sngl.dly.dos. Dos.incr.above 10 mg   those receiv.Zyprexa treatm.for manic episod.cont.ther.at same dos.   100-600 mg every 1-4 wks, usually 200 mg every 2-4 wks.
       advis.only aft.clinic.assessm. Consid.5 mg start. dos.for hepat.im-  Incr.dos.to great.than recomm.start.dos.within range of 5-20 mg/day   (S5) TABS, [P/S] T/2.6.5/180, 181.
       pairm./elderly.               only aft.clinic.assessm.at interv.of not less than 24 hrs.  Zuclopenthixol dihydrochloride.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page61.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>
             </td>
             <td width="35%"><a href="page63.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page63.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
